Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case–control study - Report - MDSpire
Advertisement
Adjunctive berberine improves hormonal, metabolic, and inflammatory profiles in women with polycystic ovary syndrome: a retrospective case–control study
Clinical Report: The Impact of Berberine on Women with Polycystic Ovary Syndrome
Overview
This study evaluates the effects of adjunctive berberine therapy alongside progesterone in women with PCOS. Results indicate significant improvements in weight, hormonal, metabolic, and inflammatory markers in the berberine group compared to controls.
Background
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting 5-10% of women of reproductive age, associated with insulin resistance and chronic inflammation. Standard treatments primarily focus on menstrual regulation but often neglect underlying metabolic issues. Berberine, known for its insulin-sensitizing and anti-inflammatory properties, may offer additional benefits when used alongside conventional therapies.
Data Highlights
Outcome
Berberine Group
Control Group
Weight Reduction
Significant
No Change
BMI Reduction
Significant
No Change
Fasting Insulin
Significant Decrease
No Change
CRP Levels
Significant Decrease
No Change
Key Findings
Berberine therapy led to significant reductions in weight, BMI, and waist-to-hip ratio (WHR).
Post-treatment LH and LH/FSH ratios were significantly lower in the berberine group compared to controls.
Total testosterone levels decreased significantly in the berberine group.
Fasting insulin, fasting blood sugar (FBS), and HOMA-IR improved significantly in the berberine group.
Inflammatory markers (CRP, TNF-α, IL-6) declined significantly only in the berberine group.
Clinical Implications
The findings suggest that berberine may enhance the effectiveness of standard hormonal treatments in women with PCOS by improving metabolic and inflammatory profiles. Clinicians may consider berberine as a potential adjunct therapy, although further randomized controlled trials are necessary to confirm these results.
Conclusion
Adjunctive berberine therapy appears to offer significant benefits in managing PCOS-related symptoms and metabolic dysfunctions. Future studies are essential to validate these findings and inform clinical practice.
